# A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

Study · id `cardio:ct-nct06151964` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06151964](<https://clinicaltrials.gov/study/NCT06151964>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06151964

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 166 participants.

## Technical summary

Registry record NCT06151964. Randomized; triple masking; primary purpose treatment. Start 2023-09-29 (actual); primary completion 2027-01-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 166 participants (enrolled count; ClinicalTrials.gov record NCT06151964, source copy `cardio:ctgov-nct06151964-2026-10-23`, retrieved 2026-10-26)
- Started: 2023-09-29 (actual) (ClinicalTrials.gov record NCT06151964, source copy `cardio:ctgov-nct06151964-2026-10-23`, retrieved 2026-10-26)
- Primary completion: 2027-01-29 (anticipated) (ClinicalTrials.gov record NCT06151964, source copy `cardio:ctgov-nct06151964-2026-10-23`, retrieved 2026-10-26)
- Completion: 2027-01-29 (anticipated) (ClinicalTrials.gov record NCT06151964, source copy `cardio:ctgov-nct06151964-2026-10-23`, retrieved 2026-10-26)
- Countries: Austria; Canada; Germany; Japan; Sweden (ClinicalTrials.gov record NCT06151964, source copy `cardio:ctgov-nct06151964-2026-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06151964-2026-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
- Acronym: CONTEMPO
- Condition: Overweight and Obesity
- Intervention (Drug): AZD9550
- Intervention (Drug): placebo
- Intervention (Drug): AZD9550 and AZD6234
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 1e9a97cc40fdeb0f562dd883a5957c8aa8e41f45dcebcb0afbe1c03d761200ba
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
